HomeFirst FDA breakthrough therapy designation in PSMA PET imaging granted to Cu-64...

First FDA breakthrough therapy designation in PSMA PET imaging granted to Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer

The United States Food and Drug Administration (FDA) has granted Clarity Pharmaceuticals’ 64Cu-SAR-bisPSMA breakthrough therapy designation for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

Breakthrough therapy designation is a process designed to expedite the development and review of drugs that are intended to treat a serious condition, and preliminary clinical evidence indicates that the drug/agent of interest may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s).

This designation is intended to get promising drugs developed and to the market as quickly and safely as possible, so that they can be available to optimise the treatment of the patients who need them most.

The benefits of a product having Breakthrough Therapy designation include:

  • All Fast Track designation features
  • Intensive guidance on an efficient drug development programme
  • Organisational commitment from the FDA involving senior managers for a more proactive, collaborative, cross-disciplinary review.

While fast track designation can be granted based on early-stage or nonclinical data, breakthrough therapy designation requires preliminary clinical evidence of a treatment effect that may represent considerable additional clinical benefit over available products in a serious condition.

Breakthrough therapy designation is also a positive indicator of potential eligibility for Priority Review due to overlapping qualifying criteria. Priority Review is requested at the time of the New Drug Application (NDA) submission and can substantially shorten the FDA’s review timeline for an NDA.

The FDA Breakthrough Therapy designation was supported by data from the phase 2 Co-PSMA trial, phase 1/2 trial and real-world evidence, which collectively indicate enhanced diagnostic performance of 64Cu-SAR-bisPSMA over standard-of-care (SOC) PSMA PET in patients with biochemical recurrence (BCR) of prostate cancer.

- Advertisment -
- Advertisment -

Most Popular

Popular categories